These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 25035153)
1. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Bruzzese D; Mazzarella C; Ferro M; Perdonà S; Chiodini P; Perruolo G; Terracciano D Transl Res; 2014 Dec; 164(6):444-51. PubMed ID: 25035153 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022 [TBL] [Abstract][Full Text] [Related]
3. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study. Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786 [TBL] [Abstract][Full Text] [Related]
4. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961 [TBL] [Abstract][Full Text] [Related]
5. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756 [TBL] [Abstract][Full Text] [Related]
6. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080 [TBL] [Abstract][Full Text] [Related]
7. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841 [TBL] [Abstract][Full Text] [Related]
8. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099 [TBL] [Abstract][Full Text] [Related]
9. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan. Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566 [TBL] [Abstract][Full Text] [Related]
10. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305 [TBL] [Abstract][Full Text] [Related]
11. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center. Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925 [TBL] [Abstract][Full Text] [Related]
12. Percent free PSA as an additional measure in a prostate cancer screen. Miele ME Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982 [TBL] [Abstract][Full Text] [Related]
13. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492 [TBL] [Abstract][Full Text] [Related]
14. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study. Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138 [TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of free PSA in early detection of prostate cancer. Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H; Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study. Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032 [TBL] [Abstract][Full Text] [Related]
18. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588 [TBL] [Abstract][Full Text] [Related]
19. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131 [TBL] [Abstract][Full Text] [Related]
20. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer. Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]